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Abstract
Oncolytic herpes simplex virus (oHSV) can potentially spread throughout the tumor, reach isolated infiltrating cells,
kill them, and deliver anticancer agents. However, the host responds to oHSV by inducing intratumoral infiltration
of macrophages that can engulf the virus, limiting the potential of this therapeutic strategy. Hypervascularity is a
pathognomonic feature of glioblastoma (GBM) and is a promising therapeutic target. Antiangiogenic treatments have
multiple benefits, including the capacity to increase oHSV efficacy by suppressing macrophage extravasation and in-
filtration into the tumor. Angiostatin is an antiangiogenic polypeptide, and interleukin-12 (IL-12) is an immuno-
stimulatory cytokine with strong antiangiogenic effects. Clinical use of each has been limited by delivery issues and
systemic toxicity.We tested a combination treatment strategy usingoHSVsexpressing angiostatin (G47Δ-mAngio) and
IL-12 (G47Δ-mIL12) in two orthotopic human GBMmodels. Intratumoral injection of G47Δ-mAngio and G47Δ-mIL12 in
mice bearing intracranial U87 or tumors derived from glioblastoma stem cells significantly prolonged survival com-
pared to each armed oHSV alone. This was associated with increased antiangiogenesis and virus spread and de-
creased macrophages. These data support the paradigm of using oHSV expressing different antiangiogenic agents
and show for the first time that oHSVs expressing angiostatin and IL-12 can improve efficacy in human GBMmodels.
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Introduction
Despite improved understanding of the molecular and physiological
features of glioblastoma (GBM), there are no curative treatments for
this brain cancer. Several modalities have been and continue to be
tested to treat these tumors, but none of these can extend life for more
than a few additional months. The median life expectancy after diag-
nosis remains approximately 15 months [1]. Genetically engineered
oncolytic herpes simplex virus (oHSV) is an attractive cancer thera-
peutic due to its capacity to selectively replicate in cancer cells, kill
them, and spread their progeny to additional cancer cells [2,3]. More-
over, the mode by which oHSV kills tumor cells differs from that of
standard anticancer agents and has a differing set of potential toxicities,
thus making oHSV useful for multimodal combination treatments
[4–7]. In addition to their oncolytic action, oHSVs can be “armed”
to express therapeutic transgenes [3,8].
Despite the biologic rationale, the efficacy of unarmed oHSV in the
clinic for brain tumors has been limited so far. Recent studies have
shown that tumor-associated macrophages and microglia limit the
replication and spread of oHSV and other oncolytic viruses [9–13].
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Antiangiogenic therapy is one of the newer strategies being pursued
to treat GBM. However, the only antiangiogenic drug that has been
approved for recurrent GBM, bevacizumab, presents only palliative
effects [14,15]. It is thus important to develop new strategies that will
improve the efficacy and safety of this treatment modality. Several
endogenous proteins that have antiangiogenic activity and oHSVs have
been identified. Thus, oHSVs armed with antiangiogenic factors may
result in significant improvement of GBM treatment, as they combine
oncolytic and antiangiogenic activities [16]. This is further emphasized
by recent data showing that antiangiogenic treatments can decrease
intratumoral macrophages, which in turn increases replication and
spread of oncolytic viruses [12,17–19].
Angiostatin, an internal fragment of plasminogen, induces regres-
sion of the tumor vasculature, inhibits cancer cell invasion, and sup-
presses tumor growth in vivo, including in GBM [20–24]. However,
because angiostatin has a very short half-life, it presents important de-
livery problems [25]. A number of replication-defective gene therapy
vectors expressing angiostatin have been developed and tested in glioma
models [19,26] but have never been tested in patients with GBM.
Interleukin-12 (IL-12) is a principal Th1 cytokine with antiangiogenic
properties. Its antiangiogenic and antitumor effects were successfully
tested when delivered to a mouse squamous cell carcinoma using oHSV
as a vector [27]. Of note, IL-12 is a mediator of angiostatin activity;
angiostatin is unable to exert angiogenesis inhibition in mice with gene-
targeted deletion of either the IL-12–specific receptor subunit IL12Rβ2
or the IL-12 p40 subunit [28]. Moreover, delivery of murine angio-
statin and IL-12 by replication-defective adenoviral vectors shrank
tumors in an immunocompetent mouse model of breast carcinoma
[29]. Therefore, we have hypothesized that a combination of oHSVs
armed with angiostatin and IL-12 could improve GBM treatment.
G47Δ [30] is an oHSV currently in clinical trial for GBM patients
[31]. We previously described G47Δ-mAngio, G47Δ armed with
mouse angiostatin, and showed that it improves survival of mice with
established U87 tumors compared to the control vector G47Δ-Empty
[19]. In addition, the same study showed that the combination of
G47Δ-mAngio with bevacizumab had an additive therapeutic effect
and suggested the advantage of combining different antiangiogenic
agents with different mechanisms of actions and adverse effects [19].
More recently, a G47Δ vector expressing mouse IL-12 (G47Δ-mIL12)
has also been engineered in our laboratory.
To test our hypothesis of combining oHSVs armedwith both angio-
statin and IL-12, we have used G47Δ-mAngio plus G47Δ-mIL12 to
treat two different human intracranial GBM tumor models: one origi-
nated from theU87 glioma cell line and the other fromMGG4, a cancer
stem cell line isolated from aGBMpatient surgical specimen [32,33]. In
both models, our results demonstrate that the combination of two anti-
angiogenic agents with different mechanisms of action, each one deliv-
ered through an oHSV vector, provides significantly better outcomes
against GBM than oHSV expressing either antiangiogenic agent alone.
Materials and Methods
Cell Lines and Cell Culture
U87 human glioma cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA) and grown in complete
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum. Human glioblastoma stem cells (GSCs; MGG4, MGG6,
MGG7, MGG8, MGG13, MGG18, MGG23, MGG27, and MGG29)
were isolated from resection specimens of newly diagnosed GBM as
previously described [32,33]. MGG30 was established from a recur-
rent GBM. BT74 was obtained from Dr Santosh Kesari (University
of California, San Diego, CA) and was originally described as GBM6
in [34]. Cultures of GSCs were maintained as spheres in serum-free
medium containing 20 ng/ml recombinant human epidermal growth
factor (R&D Systems, Minneapolis, MN) and 20 ng/ml recombi-
nant human fibroblast growth factor 2 (FGF2; Peprotech, Rocky Hill,
NJ). Passaging of the cultures was conducted by dissociating neuro-
spheres using the NeuroCult Chemical Dissociation Kit (StemCell
Technologies, Vancouver, Canada). Human umbilical vein endothelial
cells (HUVECs)were purchased fromLonza/Clonetics (Basel, Switzerland)
and grown in EGM-2 medium supplemented with the bullet kit
provided by the company, which includes 2% FBS, heparin, hydro-
cortisone, ascorbic acid, and the following human growth factors: fibro-
blast, R3-insulin, and vascular endothelial growth factor (VEGF).
HUVECs were maintained in culture for no more than 10 passages.
Viruses
The oHSV G47Δ, containing deletions of the γ34.5 and α47 genes
and an inactivating insertion of Escherichia coli LacZ into ICP6 [30],
was armed with the mouse angiostatin cDNA tagged with the hemag-
glutinin epitope (G47Δ-mAngio, [19]) or with mouse IL-12 cDNA
(G47Δ-mIL12). Mouse IL-12 cDNA (p35 and p40 separated by two
bovine elastin motifs) [35] was cloned into a shuttle vector plasmid,
pVec92-fmIL12, and inserted into pG47Δ-BAC using Cre recom-
binase (New England Biolabs, Ipswich, MA). Recombinant oHSV
was isolated as previously described [36].
Endothelial Cell Tube Formation Assay
U87 or MGG4 cells were infected with G47Δ-Empty, G47Δ-
mAngio, G47Δ-mIL12, or G47Δ-mAngio+mIL12 (total virus multi-
plicity of infection = 1) for 12 hours (U87 cells) or 24 hours (MGG4
GSCs) using Dulbecco’s modified Eagle’s medium with 2% fetal calf
serum. Infectious virus in the supernatants was blocked by adding 1%
pooled human gamma globulin (Gamastan; Grifols Therapeutics, Inc,
Barcelona, Spain) 1 hour after infection. This IgG concentration was
previously shown to block virus infection of HSV-susceptible cells.
The supernatants were then collected and used in the tube assay de-
scribed below. HUVECs (1 × 105 cells/well) were seeded on matrigel
(Matrigel Matrix; BD Biosciences, Franklin Lakes, NJ) precoated
24-well culture plates and grown in EGM-2 medium (negative con-
trol) or supernatants collected from virus-infected cells. Tube formation
was scored 6 hours later by counting the number of tubular structures
made between cells using an inverted microscope (Nikon, Melville,
NY; OPTIPHOT-2). Each supernatant was tested in triplicate. Three
random fields were chosen for counting.
Animal Studies
Female athymic nu/nu mice aged 6 to 8 weeks were obtained from
NCI Frederick (Frederick, MD). To generate intracerebral xenografts,
2 × 104 GSCs or 2 × 105 U87 cells in 2 μl of phosphate-buffered
saline (PBS) were stereotactically implanted into the right cerebrum
(2 mm lateral to the bregma at a depth of 3 mm) as described [32].
Seven days (U87) or 4 weeks (MGG4) after implantation, 2 μl of
virus [1 × 106 plaque-forming units (pfu)] or PBS was injected at the
same stereotactic coordinates. When neurologic symptoms became
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significant, mice were sacrificed by cardiac perfusion with 4% para-
formaldehyde, and the brains removed for histopathologic analysis.
All animal procedures were performed with the approval of the
Subcommittee on Research Animal Care (SRAC) at Massachusetts
General Hospital.
Immunohistochemistry
Brains were frozen in an isopentane–dry ice bath and then sectioned
by cryostat to a thickness of 5 μm through the entire tumor volume.
Every fifth section was collected for analysis. Tissue slides were dried
overnight at room temperature, fixed in ice-cold acetone, and stored at
−20°C for hematoxylin and eosin staining and immunohistochemistry
(IHC) analysis. The tissue slides were thawed and rehydrated in PBS
before staining. Each brain was analyzed for the presence of GBM cells
[human epidermal growth factor receptor (EGFR)], vascular density
(CD31), macrophage infiltration (F4/80), and VEGF expression as fol-
lows: endogenous proteins and peroxidases were blocked with serum-
free protein block and peroxidase-blocking reagent (DakoCytomation,
Glostrup, Denmark). Mouse IgG was blocked with mouse on mouse
reagent (Vector Laboratories, Burlingame, CA). Sections were then
incubated overnight at 4°C with each of the following primary anti-
bodies: mouse anti-human EGFR (M3563; Dako), rat anti-mouse
CD31 (550274; BD Pharmingen, Franklin Lakes, NJ), rat anti-mouse
F4/80 (MCA497RT; Serotec, Kidlington, Oxford, United Kingdom),
andmouse anti-humanVEGF antibody (555036; BDBiosciences). This
was followed by incubation with anti-rat or anti-mouse IgG-HRP sec-
ondary antibody (Amersham, Piscataway, NJ). Liquid DAB Substrate
Chromogen System (DakoCytomation) was used for detection. To
quantify CD31 or VEGF immunopositive areas, NIH ImageJ software
assisted with the color deconvolution plugin was used to analyze
six randomly chosen high magnification microscopic images per tumor.
Intratumoral G47Δ spread was analyzed through staining of viral
β-galactosidase activity with X-gal reagent (5-bromo-4-chloro-3-inodolyl-
β-D-galactopyranoside; Sigma, St Louis, MO; 0.4 mg/ml in PBS) added
to the acetone-fixed slides and incubated at 37°C for 4 hours. In all cases,
the sections were counterstained with hematoxylin, dehydrated with
increasing concentrations of ethanol, and fixed in xylene. NIH ImageJ
software was used to calculate the viral infected area in 10 different
tumor sections cut across the whole tumor volume.
Statistical Analysis
Statistical analysis of animal survival was performed with log-rank
(Mantel-Cox) test. All other experiments were analyzed with two-
sided analysis of variance test followed by means comparisons with
post hoc Tukey’s test (GraphPad Prism software). P < .05 was con-
sidered to be statistically significant. All error bars indicate SDs.
Results
Antiangiogenic Effects of Combination G47Δ-mAngio Plus
G47Δ-mIL12 Treatment in the U87 Human Glioma
Model In Vitro
We first tested the effects of supernatants from U87 cells infected
with G47Δ-Empty, G47Δ-mAngio, G47Δ-mIL12, or G47Δ-mAngio
Figure 1. Antiangiogenic effect of supernatants collected from virus-infected U87 cells in vitro. (A) Representative images of tubular struc-
tures formed by HUVECs when grown on a matrigel substrate with supernatants from infected U87 cells. The bar indicates 0.5 mm.
(B) The number of tubes counted when HUVECs were grown in the presence of supernatants from U87 cells infected with G47Δ-Empty
(Empty; 35.25 ± 0.85), G47Δ-mAngio (mAngio; 13.25 ± 1.11), G47Δ-mIL12 (mIL12; 13.50 ± 0.65), G47Δ-mAngio + G47Δ-mIL12 (mAngio +
mIL12; 5.25 ± 0.85), or EGM (−; 38.25 ± 1.12). The bars indicate average number of tubes ± SD. Statistically significant differences
were observed for Empty versus mAngio, P < .0001; Empty versus mIL12, P < .0001; mAngio versus mAngio + mIL12, P = .0012,
mIL12 versus mAngio + mIL12, P = .0006; EGM(−) versus mAngio + mIL12, P < .0001; EGM(−) versus mAngio, P < .0001; EGM(−)
versusmIL12, P < .0001.
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plus G47Δ-mIL12 combination (mAngio + mIL12) in a HUVEC
tube formation assay in vitro (Figure 1A). While supernatants from
U87 cells infected with either G47Δ-mAngio or G47Δ-mIL12 sig-
nificantly decreased tube formation in vitro compared with control,
the combination of the two viruses further inhibited tube formation
(Figure 1, A and B).
G47Δ-mAngio Plus G47Δ-mIL12 Treatment of the U87
Glioma In Vivo
We next determined the therapeutic benefit of G47Δ-mAngio and
G47Δ-mIL12 individually and in combination in intracranial U87
gliomas established in athymic mice. Intratumoral injection of each
virus alone (1 × 106 pfu) had a significant and similar therapeutic
effect and extended median survival from 48 days (PBS) and 53 days
(G47Δ-Empty) to 66 (G47Δ-mAngio) and 67 (G47Δ-mIL12) days.
The combination of mAngio + mIL12 (0.5 × 106 pfu each) was sig-
nificantly better than either virus alone, with seven of eight (87.5%)
tumor-bearing mice surviving at least 150 days (about three times
median survival of PBS; Figure 2A). At that point, the surviving mice
were sacrificed and the brains were removed for histopathologic
analysis, which revealed the presence of only few dispersed tumor
cells surrounded by infiltrative neutrophils and macrophages (Fig-
ure 2B). These results demonstrate a significant therapeutic advantage
of using these two oHSVs together in treating orthotopic GBM
tumors in mice.
Screening of CD31 and VEGF Expression in Human
GSC Xenografts
Although U87 is a highly vascular and commonly used glioma
model, it does not present the cellular heterogeneity or histopathologic
hallmarks commonly seen in human GBMs; therefore, we sought to
test this combination therapy on human GSC-derived tumors, which
recapitulate pathologic features of the GBM from which they were
isolated. We screened a cohort of GSC intracerebral tumors derived
from 11 different GSC lines for CD31+ vessel density and VEGF ex-
pression intensity to establish the relative angiogenic levels in each of
them (Figure 3). MGG4 demonstrated the highest CD31+ vascularity,
characterized by aberrantly tortuous and dilated tumor-associated vas-
culature (Figure 3A), which was associated with strong VEGF immu-
nopositivity within the tumor (Figure 3). Thus, this tumor model was
chosen to test the combination mAngio + mIL12 treatment. The ex-
pression of CD31+ and VEGF in different GSC lines were quantified
(Figure 3B).
G47Δ-mAngio Plus G47Δ-mIL12 Treatment of the Human
GSC MGG4 Model In Vitro and In Vivo
To evaluate the antiangiogenic activity of virus therapy, as with
U87, we first tested the effects of supernatants collected from in-
fected MGG4 cells on HUVEC tube formation on matrigel in vitro
(Figure 4A). Supernatants derived from G47Δ-mAngio or G47Δ-
mIL12 alone decreasedHUVEC tube formation, whereas the combina-
tion of mAngio + mIL12 further inhibited tube formation (Figure 4B).
We then determined the therapeutic benefit of G47Δ-mAngio
(mAngio) and G47Δ-mIL12 (mIL12) individually and in combina-
tion on intracranial MGG4-derived tumors established in nude mice.
G47Δ-mAngio or G47Δ-mIL12 alone had a similar therapeutic bene-
fit in this tumor model and were significantly better than G47Δ-Empty
(lacking any therapeutic transgene; Figure 5). In this model, G47Δ-
Empty was not any better than PBS, although each armed virus alone
was better than PBS or G47Δ-Empty. Importantly, the combination
of mAngio + mIL12 significantly extended median survival from
98 days for the groups treated with either PBS or G47Δ-empty to
Figure 2. Kaplan-Meier analysis of survival after combination treatment in U87 intracranial glioma model. (A) Survival of mice with
established U87 intracranial tumors treated intratumorally with PBS, G47Δ-Empty, G47Δ-mAngio, G47Δ-mIL12, and G47Δ-mAngio +
G47Δ-mIL12 (1 × 106 pfu on day 7; n = 8/group). The P values for each pairwise comparison are indicated. (B) Histopathologic analysis
of a representative brain taken from the mAngio + mIL12 treatment group that remained asymptomatic 150 days after tumor implan-
tation. The same section is shown at two different magnifications (bar a indicates 5 mm, and bar b indicates 2 mm). Left panel: The
circle indicates the area around the site of tumor implantation. Right upper panel: Hematoxylin and eosin. Right lower panel: EGFR IHC.
Arrows indicate area where dispersed cancer cells and inflammation were observed.
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136 days (Figure 5). Furthermore, mice receiving the combination
virus treatment survived significantly longer than those receiving
either G47Δ-mAngio or G47Δ-mIL12 alone (Figure 5).
G47Δ Distribution in GSC-Derived Tumors
Antiangiogenic treatments have been shown to increase intratumoral
virus distribution by suppressing infiltration of peripheral macrophages
[12,17–19]. We therefore examined intratumoral virus distribution
through X-gal staining 3 days after virus injection (Figure 6) and eval-
uated intratumoral levels of angiogenesis (VEGF and CD31 markers)
and macrophages (F4/80) in the same tumors by IHC (Figure 7).
Three days after virus injection is the earliest time point when, in
the absence of adjuvant therapy, oHSV oncolytic activity is completely
suppressed [10] (Figure 6). Indeed, reduction of virus-induced intra-
tumoral macrophages was shown to be associated with increased viral
spread [11].
To quantify LacZ expression inside the tumor, we used human
EGFR staining to localize tumor and calculated the percentage of
tumor area stained with X-gal (Figure 6). G47Δ-Empty exhibited
only a small area of infected tumor cells (Figure 6). In contrast,
G47Δ-mAngio and G47Δ-mIL12 had more extensive intratumoral
virus distribution. Combination treatment further increased virus
distribution, which was dispersed through more than 50% of the
tumor (Figure 6B). Therefore, increased efficacy of the combined
G47Δ-mAngio + G47Δ-mIL12 treatment was associated with
increased virus spread.
Figure 3. Immunohistochemical analysis of vascularity in human GSC xenografts. (A) Sections of the central tumor show tumor vascularity
(CD31, brown) and VEGF expression (VEGF, diffuse brown staining of the secreted molecule) from human GSCs: MGG4, MGG6, MGG7,
MGG8, MGG13, MGG18, MGG23, MGG27, MGG29, MGG30, and BT74. Two representative fields from different areas of the same tumors
are shown for each protein. The bar indicates 0.5 mm. (B) The graphs show the percentage of area positive for CD31 or VEGF expression.
The bars indicate the average percentage of positive areas from six independent fields ± SD.
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Tumor vascularity and VEGF expression were decreased by treat-
ment with individual armed viruses and even more by the combina-
tion of G47Δ-mAngio with G47Δ-mIl12 (Figure 7). G47Δ-Empty
infection was accompanied by the presence of dense active macro-
phages, whereas the areas of G47Δ-mAngio or G47Δ-mIL12 infection
were characterized by necrosis and decreased macrophage density
compared to G47Δ-Empty. The combination of G47Δ-mAngio with
G47Δ-mIL12 not only resulted in a large decrease in vascularity
(CD31), VEGF (Figure 7A), and EGFR expression (Figure 6) but also
abrogated the infiltration of mature macrophages (F4/80) seen with
G47Δ-Empty infection (Figure 7A). Therefore, increased efficacy of
combined G47Δ-mAngio plus G47Δ-mIL12 treatment was associated
with decreases in both tumor vascularity and macrophage infiltration,
which may have facilitated virus spread. The expression of VEGF and
CD31 in different groups were quantified (Figure 7B).
Discussion
We provide evidence that treatment of GBM with oHSVs expressing
IL-12 and angiostatin can improve outcomes. Indeed, combining two
oHSVs, one expressing IL-12 and the other angiostatin, increases sur-
vival of animals bearing either of two different models of human
GBM, and increased antiangiogenesis induced by the combination
of IL-12 and angiostatin was observed in vitro and in vivo. This
is in agreement with previously published data showing IL-12 as a
mediator of the angiostatin-initiated antiangiogenic pathway [28,29].
Immunohistologic analysis of tissues after treatment has provided
information on the cellular and molecular mechanisms underlying
this therapy: 1) treatment with G47Δ-mIL12 + G47Δ-mAngio de-
creases expression of angiogenic markers (CD31 and VEGF) and
CD31+ vessels to a greater degree than either virus alone, thus con-
firming the improved antiangiogenic effect of combining viruses
expressing these two molecules [28,29]; 2) decreased angiogenesis cor-
responds with a decrease of macrophage infiltration as previously
described [12,19], which results in 3) increased intratumoral viral
spread [10,11].
For this study, we have selected two highly angiogenic tumors
because angiogenesis is a primary target of the treatment. Less angio-
genic tumors may be less responsive to the treatment, but this would
be a concern only on a limited subgroup of GBM since angiogenesis
is a very common feature of GBMs. The combination of two viruses
expressing mAngio and mIL-12 led to a greater therapeutic effect in
U87 tumors than in MGG4. This is probably due to the fact that U87
cells are more permissive to G47Δ replication and thus express higher
amounts of the transgenic cytokines (data not shown). Indeed, when
taken individually, each virus showed a better therapeutic effect in
U87 cells than in MGG4 GSCs.
The use of oncolytic viruses expressing antiangiogenic factors for
tumor treatment has been previously described [8,16]. However,
only more recently, studies have shown that decreased angiogenesis
not only prevents tumor growth but also allows increased lysis of
tumor cells by the viruses, thus emphasizing the importance of com-
bining these two therapeutic strategies [12,17–19]. Herein, we have
expanded this concept by combining oHSVs expressing two different
antiangiogenic factors, one of which (IL-12) is a mediator of the
activity of the other (angiostatin).
Figure 4. Antiangiogenic effects of supernatants collected from
virus-infected MGG4 GSCs in vitro. (A) Representative tubular struc-
tures formed by HUVECs when grown on a matrigel substrate
with supernatants from infected MGG4 GSCs. The bar indicates
0.5 mm. (B) The number of tubes counted when HUVECs were
grown in the presence of supernatants from MGG4 GSCs infected
with G47Δ-mAngio (mAngio; 14.25 ± 1.11 tubes), G47Δ-mIL12
(mIL12; 14.75 ± 1.44 tubes), G47Δ-mAngio + G47Δ-mIL12
(mAngio +mIL12; 3.75 ± 0.48 tubes), or EGM (−; 41 ± 2.35 tubes).
The bars indicate average number of tubes ± SD. Statistically sig-
nificant differences were observed for mAngio versus mAngio +
mIL12, P < .0001; mIL12 versus mAngio + mIL12, P = .0003;
EGM(−) versus mAngio + mIL12, P < .0001; EGM(−) versus
mAngio, P < .0001; and EGM(−) versusmIL12, P < .0001.
Figure 5. Kaplan-Meier analysis of survival after combination treat-
ment of MGG4 GBM. Survival of mice (n = 10/group) with estab-
lished MGG4 intracranial tumors and treated with PBS (median
survival = 98 days), G47Δ-Empty (Empty; 98 days), G47Δ-mAngio
(mAngio; 113 days), G47Δ-mIL12 (mIL12; 112 days), and G47Δ-
mAngio + G47Δ-mIL12 (mAngio + mIL12; 136 days). The P values
for each pairwise comparison are indicated.
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Interestingly, IL-12 was shown to induce immune responses in pre-
clinical models of GBM and other malignancies, when delivered through
oHSV vectors [37–44]. This may seem in contrast with the inhibition
of macrophage infiltration that we observe. However, such differences
may be due to the occurrence of different immune responses at different
times following an inflammatory stimulus. In this respect, we tested the
tissues at 3 days following oHSV injection, a time of acute inflamma-
tion in response to the virus. IL-12–induced immunity against the
cancer would be expected to be observed at later time points. In addi-
tion, because these experiments were done with athymic mice, we could
not determine whether there was establishment of adaptive antitumor
immune responses. It may be that the integral immune system of an
Figure 6. Virus infection of intracranial MGG4 tumors. (A) Nude mice with established intracranial MGG4 tumors were treated with intra-
tumoral injection of G47Δ-Empty (Empty), G47Δ-mAngio (mAngio), G47Δ-mIL12 (mIL12), and G47Δ-mAngio + G47Δ-mIL12 (mAngio +
mIL12; n = 3/group) and sacrificed 3 days later. Sections of the central tumor show viral distribution [viral β-galactosidase activity (LacZ),
blue] and tumor cells (EGFR, brown). The bar indicates 2 mm. (B) Quantification of LacZ staining in the tumor area. Six dots per group
represent six different fields in three different tumors (two fields per tumor). The percentage of positive areas in tumor is calculated as
LacZ-positive areas/EGFR-positive areas × 100 (%). The bars indicate the average percentage of positive areas from six independent fields.
Figure 7. Immunohistochemical analysis of tumors. (A) Tumors were intratumorally injected with G47Δ-mAngio + G47Δ-mIL12 (mAngio +
IL-12), G47Δ-mAngio, G47Δ-mIL12, G47Δ-Empty, or PBS (n= 3/group) and sacrificed 3 days later. Sections of the central tumor area show-
ing VEGF expression (VEGF, diffuse brown staining of the secreted molecule), tumor vascularity (CD31, brown), and macrophage infiltration
(F4/80, brown) in adjacent sections. The bar indicates 0.5 mm. (B) Quantification of VEGF and CD31 expression in different groups. The
percentage of positive areas in tumor is defined as the percentage of VEGF or CD31-positive areas per field. The P values are indicated.
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immunocompetent model will limit increased viral replication in the
presence of excessive IL-12. Further characterization of this therapy
requires detailed testing in an immunocompetent mouse model and
analysis of potential establishment of anticancer immunity.
Overall, these data demonstrate the ability of oHSV-induced com-
binatorial antiangiogenic therapy to improve the efficacy of human
GBM treatment and suggest that further studies are indicated with a
goal toward clinical translation.
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